MedTrace Logo

Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years

NCT06216093 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-06-15

No results posted yet for this study

Summary

Phase 1 clinical trial to evaluate the safety of RSV-1 and RSV-2 vaccines in healthy adults aged 19 to 80 years who have voluntarily given written consent to participate in this study.

Conditions

  • Respiratory Syncytial Virus Infections
  • Respiratory Syncytial Virus (RSV)

Interventions

BIOLOGICAL

EuRSV

Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.

OTHER

Placebo Comparator

Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.

Sponsors & Collaborators

  • EuBiologics Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-08
Primary Completion
2025-07-31
Completion
2025-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06216093 on ClinicalTrials.gov